Last reviewed · How we verify

Non-small cell lung cancer — Treatment Landscape & Competitive Intelligence

Non-small cell lung cancer (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Non-small cell lung cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
PF-06939999 in combination with docetaxel pf-06939999-in-combination-with-docetaxel Pfizer Small molecule inhibitor Specific protein kinase Not yet determined
Gavreto PRALSETINIB Rigel Pharms Kinase Inhibitor [EPC] RET 2020-01-01
Lorbrena lorlatinib Pfizer Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2018-01-01
Imfinzi durvalumab AstraZeneca Programmed Death Ligand-1 Blocker [EPC] Programmed cell death 1 ligand 1 2017-01-01
Alunbrig brigatinib Takeda Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2017-01-01
Alecensa alectinib Hoffmann-La Roche Kinase Inhibitor ALK tyrosine kinase receptor 2015-01-01
Portrazza NECITUMUMAB Eli Lilly Co Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2015-01-01
Zykadia ceritinib Novartis Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2014-01-01
Ofev NINTEDANIB Boehringer Ingelheim Kinase Inhibitor Receptor-type tyrosine-protein kinase FLT3 2014-01-01
Cyramza RAMUCIRUMAB Eli Lilly Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] Vascular endothelial growth factor receptor 2 2014-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 13 drugs in Non-small cell lung cancer
  2. M.D. Anderson Cancer Center · 2 drugs in Non-small cell lung cancer
  3. Accord Hlthcare · 2 drugs in Non-small cell lung cancer
  4. Pfizer Inc. · 2 drugs in Non-small cell lung cancer
  5. Boehringer Ingelheim · 2 drugs in Non-small cell lung cancer
  6. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in Non-small cell lung cancer
  7. Bristol-Myers Squibb · 1 drug in Non-small cell lung cancer
  8. Actavis · 1 drug in Non-small cell lung cancer
  9. Eli Lilly · 1 drug in Non-small cell lung cancer
  10. David Adelstein · 1 drug in Non-small cell lung cancer
  11. Eli Lilly Co · 1 drug in Non-small cell lung cancer
  12. Concordia Labs Inc · 1 drug in Non-small cell lung cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-small cell lung cancer:

Cite this brief

Drug Landscape (2026). Non-small cell lung cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-small-cell-lung-cancer. Accessed 2026-05-16.

Related